iShares U.S. Pharmaceuticals ETF (IHE)
An exchange-traded fund listed on AMEX. A fund is not a company: it has no filed accounts of its own here, and it is never ranked beside companies. Every figure below is market data, with the day it was supplied.
Price
Last close 101.12 USD on Oct 15, 2026. Market data, supplied Oct 15, 2026.
What it costs
| Expense ratio | 0.37% |
| Assets under management | 1.54B USD |
| Net asset value per share | 99.46 USD |
| Inception | May 1, 2006 |
| Sponsor | IShares |
| Asset class | Equity |
| Holdings the fund reports | 53 |
Market data, supplied Oct 15, 2026.
What it holds
The largest 25 by weight of the 56 holdings in the snapshot of Oct 15, 2026. A fund is marked as a fund, and a holding that is not a company's share (a bond, a bill, cash, an option or a swap) is marked as not a company.
| # | Holding | Weight |
|---|---|---|
| 1 | ELI LILLY | 24.79% |
| 2 | JOHNSON & JOHNSON | 21.92% |
| 3 | PFIZER | 4.85% |
| 4 | ZOETIS INC CLASS A | 4.74% |
| 5 | MERCK & CO INC | 4.61% |
| 6 | VIATRIS | 4.52% |
| 7 | ROYALTY PHARMA PLC CLASS A | 4.49% |
| 8 | BRISTOL MYERS SQUIBB | 4.24% |
| 9 | JAZZ PHARMACEUTICALS PLC | 3.07% |
| 10 | ELANCO ANIMAL HEALTH | 2.54% |
| 11 | CORCEPT THERAPEUTICS | 2.50% |
| 12 | AXSOME THERAPEUTICS | 1.63% |
| 13 | LIGAND PHARMACEUTICALS | 1.33% |
| 14 | DEFINIUM THERAPEUTICS INC | 1.04% |
| 15 | INDIVIOR PHARMACEUTICALS INC | 0.91% |
| 16 | ORGANON | 0.81% |
| 17 | VERADERMICS | 0.80% |
| 18 | AMNEAL PHARMACEUTICALS INC CLASS A | 0.79% |
| 19 | EDGEWISE THERAPEUTICS | 0.68% |
| 20 | TARSUS PHARMACEUTICALS | 0.63% |
| 21 | AMYLYX PHARMACEUTICALS | 0.63% |
| 22 | LIQUIDIA | 0.57% |
| 23 | ENLIVEN THERAPEUTICS | 0.57% |
| 24 | SUPERNUS PHARMACEUTICALS | 0.53% |
| 25 | PRESTIGE CONSUMER HEALTHCARE | 0.52% |
Market data, supplied Oct 15, 2026.
Sector weights
| Pharmaceuticals | 99.91% |
| Cash and/or Derivatives | 0.09% |
Market data, supplied Oct 15, 2026.
Country weights
| United States | 96.43% |
| Ireland | 3.57% |
Market data, supplied Oct 15, 2026.
Look-through value
Earnings yield, P/E and book yield of the holdings taken together: n/a. Look-through figures are not measured for this fund yet.